Scientific excellence in the field of health
For the second consecutive year, Sanofi and Institut Pasteur recognized four researchers for their innovative research in Life Sciences. The Sanofi Institut Pasteur awards were created to promote scientific excellence that contributes to advances in health.
Professor Peter C. Agre, 2003 Nobel Prize in Chemistry and chairman of the selection jury, Christopher A. Viehbacher, Chief Executive Officer, Sanofi and Professor Christian Bréchot, President of the Institut Pasteur were on hand for the awards ceremony at Sanofi headquarters in Paris.
The coming together of Sanofi and Institut Pasteur for these Awards reflects two of the core elements required in improving global health - innovation and partnership. Sanofi is proud to support this initiative.
Outstanding work of four international researchers highlighted
Selected from among 80 scientists nominated, the winners were honored for their outstanding work in four major research areas:
Dr. Carolina Barillas-Mury, PhD, Senior Investigator at the NIH National Institute of Allergy and Infectious Diseases, USA, was rewarded in the field of “tropical and neglected diseases”.
For her scientific contributions to the understanding of mosquito immune responses that affect malaria transmission. Her research incorporates insect biology, physiology and genetic strategies to understand the ways malaria parasites deal with mosquitos’ antiplasmodial defenses to survive and multiply.
Dr. Christelle Desnues, PhD, works for the CNRS Unit of Emerging Tropical Diseases at the La Timone University hospital, Marseille, France. She was nominated in the category of “Innovative Approaches to disease prevention, including vaccines”.
She has been honored for her work in viral metagenomics and microbial ecology and in support of her current research on the diversity of viruses in the environment associated with humans.
Pr. Roy Kishony, PhD, Harvard Medical School, USA, and Technion University, Haïfa, Israel, was nominated in the category of “New approaches to drug resistance”.
He has established the quantitative principles governing evolution of resistance in multi-drug treatments, creating a new discipline at the intersection of pharmacology, systems biology, and evolution. He has been honored for his original systems biology research explaining the principles governing the evolution of drug resistance.
Pr. Alain Fischer, MD, PhD, Director of the Pediatric Immunology Unit (Inserm), Hôpital Necker-Enfants Malades, Professor at the Paris Descartes University, Paris France, was nominated in the “Immunology, immunomodulation, immunogenetics and translational technologies” category.
He was selected by the Sanofi - Institut Pasteur jury for elucidation of the molecular basis of more than 30 primary immunodeficiencies in young children and the development of the first effective gene therapy in humans.